Aberrant Expression of CD56 in Patients With Hematologic Malignancies.

Sponsor
Asmaa Hassan mohamed Abdel Mawjoud
Study ID
NCT04546945
Status
Recruiting
Apply to this trial

Conditions

  • Hematologic Malignancies

Eligibility Criteria

Sex
ALL
Age
N/A - N/A
Healthy Volunteers
Accepted

Interventions

  • CD56 — DIAGNOSTIC_TEST
    detection of CD56 by flow cytometry

Study Details

CD56(cluster of differentiation 56) was found to be ectopically expressed in multiple myeloma . A met analysis indicated that CD56 over expression may be an adverse prognostic factor in AML. To the best of our knowledge, no available data the expression pattern of CD56 in other Hematologic malignancies. This work is designed to evaluate the expression pattern of CD56 in hematologic malignancies.

Key Dates

First listed
Sep 14, 2020
Start date
Mar 20, 2027
Status verified
Mar 2026
Primary completion
Jun 30, 2027
Completion
Dec 30, 2027

Study Design

Enrollment
38 participants (estimated)

Arms

  • Arm: control cases
    normal healthy person
  • Arm: Patients
    Patients with hematologic malignancies. Newly diagnosed.

Primary Outcome Measure

To identify the Pattern of expression of CD56 in hematologic malignancies. [ Time Frame: 1 years ]

Central Contacts

Related Studies